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This paper investigates the changing landscape of biotechnology incubators in the UK and evidences 
their evolution from 1999 to 2017.  We highlight the changing policy environment for biotechnology 
incubators and begin to investigate the evolution of UK biotechnology incubators from facilities that 
primarily support the commercialisation of intellectual property derived from universities to 
facilities that reuse former pharmaceutical research and development laboratories and collocate with 
operational pharmaceutical companies. This study uses two desk-based surveys that provide snap-
shots of 21 biotechnology incubators taken in December 2012 and December 2017. The surveys 
provide a detailed examination of the characteristics of UK biotechnology incubators and their tenant 
companies. We observe the appearance of biotechnology incubators with an economic regeneration 
remit, funded by and working in partnership with regional government (BioPark Hertfordshire & 
BioCity Nottingham). We also observe the appearance of corporate biotechnology incubators 
(Akcomak, 2009) co-located on operational pharmaceutical research and development sites with an 
open innovation remit e.g. Astra Zeneca (Manchester), GlaxoSmithKline (Stevenage) and Boots 
(Nottingham). We propose that regional and national policy initiatives and changes in the business 
model of large pharmaceutical companies have been the main drivers for the evolution of 
biotechnology incubators in the UK.  
 
1. Introduction 
Since the 1990s, public policy makers and private investors have been creating biotechnology incubators with the aim 
of obtaining a foothold in what many presumed was one of the hottest future industries.  Start-ups and early stage life 
science companies require access to specialist premises, services, technical support and seed investments not 
traditionally available on science parks and business parks. With its science-based characteristics biotechnology relies 
on a strong knowledge base that incorporates a number of different scientific disciplines. Its reliance on a series of 
relatively recent scientific breakthroughs means it is a relatively young sector largely comprising small entrepreneurial 
firms which rely on having a close relationship to universities and the scientific environment. Public support for 
biotechnology is mainly driven by the expectation that the exploitation of biotechnology research can provide 
economic, social and environmental benefits (Reiss 2005). This is made evident by the ‘science city’ status that UK 
cities use to boost their local economy. At a broad level national Government have been keen to encourage skills and 
infrastructure development in the life science sector to cater to their internal healthcare needs and develop an 
internationally competitive industry whilst connecting with wider social aims such as local economic development and 
job creation (Misra, 2010).  
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A favoured policy instrument at a local and regional level has been the introduction of biotechnology incubators to 
support the growth and prosperity of the biotechnology sector. The justification for government intervention is that 
systematic failure in the market has limited the ability of small technology-based firms to survive and overcome the 
early stages of firm creation OECD (1997). The UK biotechnology sector is traditionally clustered near areas of 
scientific expertise, for example, universities in London and the South East such as Oxford and Cambridge (Smith et al. 
2012). Access to venture capital finance is also a contributing factor in the evolution of the UK’s biotechnology 
industry, for the industry to grow investment is required (Lerner 2009). This has meant that biotechnology firms have 
traditionally grown in localities that are close to financial markets and universities with a strong research base i.e. 
London and the South East of England 
 
A biotechnology incubator provides premises, facilities, office space and business support specifically tailored to the 
needs of tenant companies. Their aim is to nurture and encourage growth and sustainability amongst new life science 
start-up companies. There is a handful of biotechnology incubators that were established during the 1990s in the UK 
however the majority have opened more recently over the last fifteen years. Some biotechnology incubators were 
purpose built and others regenerated former large pharmaceutical research and development laboratories that had closed 
down. The common theme that is shared between all biotechnology incubators in the UK is their provision of laboratory 
space (either chemical or biological), write-up space or office space and one form or another of infrastructure support 
for new and emerging biotechnology and medical technology companies. 
 
The first biotechnology incubators appeared in the UK during the 1990s in response to government policy initiatives 
that were aimed at increasing the commercialization of intellectual property from UK universities (Cooke 2004). 
Biotechnology incubators have been used in a number of ways, Regional Development Agencies (RDA’s) had begun to 
use biotechnology incubators as a mechanism to attract inward investment and create highly skilled jobs (Ehret et al. 
2012). Science parks were using biotechnology incubators as a method to link small agile biotechnology firms with 
large established companies (Bernasconi et al. 2006). Finally, hospitals have started to work with small life science 
companies to develop therapeutics and medical devices and large pharmaceutical companies used biotechnology 
incubators as a method to actively support open innovation (Chesbrough 2006). 
2. Literature 
2.1 Biotechnology incubation 
A primary purpose of ‘business incubation’ is based upon the aim of reducing the rate of start-up failure in small 
businesses by providing assistance during the critical stage of business development in the early years (Aerts, 2007). 
The concept of a traditional business incubator involves the utilisation of a building in which a group of new or growing 
businesses locate in or operate from with lower overhead costs such as subsidised rental rates for their accommodation 
(Kuratko and  Lafollette 1987). An extension to this definition is provided by Hannon (2004), the purpose of the 
business incubator is to provide the opportunity for accelerating growth and development of the incubatees so more 
could be achieved than in the ‘external’ natural environment. Grimaldi et al. (2005) argued that the incubator 
environment aims to link technology, capital and know-how to leverage entrepreneurial talent and speed up the 
development of new technologies. 
 
Biotechnology incubators differ from traditional business incubators in terms of the type of tenant companies that 
biotechnology incubators support. Unlike in other high tech industries such as IT, nanotechnology, clean technology 
and food technology it can take up to 20 years for a biotechnology company to successfully to bring a drug to market 
(Pisano, 2006).  The main purpose of biotechnology incubators is to speed-up the business development of life science 
companies by providing access to early stage seed investment, reducing the uncertainty in the early phases of 
development, and shortening the ‘time-to-market.’ Biotechnology incubators are a supportive environment designed to 
hatch new biotechnology companies (BERR, 2008).   
 
Reiss et al. (2005) noted that public support for a growing biotechnology sector is mainly driven by the assumption that 
the exploitation of biotechnology research can provide economic, social and environmental benefits.  Similarly, Misra 
(2010) observed that at a broad level Governments are keen to encourage skills and infrastructure development in the 
life science sector to cater to their internal healthcare needs and develop an internationally competitive industry whilst 
connecting with wider social aims such as local economic development and job creation. A favoured policy instrument 
at a local and regional level was the introduction of biotechnology incubators to support the growth and prosperity of 
the biotechnology sector. The justification for Government intervention is that systematic failure in the market limited 
the ability of small technology-based firms to survive and overcome the early stages of firm creation OECD (1997).  
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2.2 Biotechnology clusters 
The structure of the biotechnology sector is different to the pharmaceutical industry. While the pharmaceutical industry 
comprises a small number of widely dispersed large companies, in contrast the biotechnology sector comprises a large 
number of small companies. According to Lawton-Smith (1999) a characteristic of the biotechnology sector is its intimate 
and continuing relationship with university research. Similarly, Swann (1998) noted that a distinctive attribute of the 
biotechnology sector in terms of growth is its tendency to cluster. 
The literature on biotechnology clusters can be separated into three distinct areas i) research that defines the concept of 
clusters, ii) research that investigates the advantages of industry clustering for high tech firms, and iii) biotechnology 
clustering in the UK covering both the North and South of England. The phenomenon of industry clusters has been 
investigated within several different contexts including the cotton industry in the early 19th century, the emergence of the 
computing industry in the 20th century and the growth of the biotechnology sector in the 21st century. Clustering is not 
a new concept however it has only relatively recently been applied as a tool of analysis to an emerging biotechnology 
sector. 
Research undertaken by Swann (1998) and Cooke (2002) pointed towards a tendency for biotechnology companies to 
cluster near universities, centres of research excellence and large pharmaceutical companies. One key feature of the 
biotechnology sector is its reliance on a source of scientific knowledge. In addition to the work carried out by Cooke 
(2006) and Swann (1998), Bernasconi et al. (2006) and Lawton-Smith et al. (2005) stated that the UK biotechnology 
sector was developed with clusters of activity in the East and South East very close to universities and large 
pharmaceutical companies. Swann et al. (1998) noted the impact of the pharmaceutical industry clustering in the UK.  
These knowledge sensitive biotechnology firms increasingly created clusters in Cambridge, Oxford and London (Cooke 
2003). This feature of agglomeration of life science activity and the growth of biotechnology clusters was well established 
in London and the South East by the early 1990s . Cooke (2001) noted that there was close collaboration between local 
biotechnology firms in Oxford and that a number of significant biotechnology firms were Oxford University spin-outs. 
According to Bernasconi et al. (2006) and Cooke (2001) this relatively young biotechnology sector largely comprised 
small entrepreneurial firms that relied on close relationships to universities and the scientific environment in order to form 
clusters of activity.  
In addition to close connections to the local science base, biotechnology clusters were also geographically close to large 
pharmaceutical companies, for example in the East of England. The competitive advantage to be gained was that co-
financing new biotechnology firms were often provided by pharmaceutical companies such as GlaxoSmithKline, MERCK 
and ROCHE all of which had research and development facilities within a 25 mile radius of Cambridgeshire (Garnsey 
2005). As described by Marshall (1920) and Porter (1996), there were specific competitive advantages that can be gained 
from industry clusters.  
The literature suggests that biotechnology clusters have not developed in all regions of the UK, there was relatively very 
little in the way of biotechnology clusters in the Midlands and Yorkshire & Humberside. This is partly due to the 
geographical distribution of biotechnology clusters. They are closely linked to the sources of scientific knowledge i.e. 
universities that are major centres of life science research. Therefore we can expect biotechnology cluster to be unevenly 
distributed across the UK because universities with a strong life science base are unevenly distributed, with the major 
centres in the South and South East. Hence Cities in the Midlands and Yorkshire & Humberside do not feature any 
biotechnology clusters in the analysis of UK biotechnology clusters undertake by Swann (1998 p214) and Cooke (2001).  
2.5 Growth and development of incubators 
It has been proposed by Allen (1990) that the life cycle of an incubator consists of three stages, stage one is gaining 
control of a site, successfully securing finance for construction and renovation and attracting initial tenants. Stage two is 
business development and the nurturing of new businesses. Similarly, Bergek (2008) noted that making links with 
professionals and consultants that can provide management advice to tenants firms. Stage three is maturity, the facility  
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begins to tighten entrance policies, accelerate graduation and exit strategies which involve tenants moving on into the big 
wide world or expanding operations into new geographical areas or new markets. According to Bergek (2008), as the 
incubator moves through this life cycle the quality and quantity of development outcomes are higher. Hamdani (2006) 
also makes use of the life cycle of a business incubator to conceptualise and measure the incubation process. 
Gassman (2006) took a resource-based view to provide an explanatory model that measures the intangible resources and 
tacit knowledge that are difficult to detect within a corporate incubator. This was achieved by differentiating between the 
characteristics of non-profit and for profit incubators within the context of corporate incubators by focusing on the nature 
of relationships between the corporate incubator and the parent corporation and the analysis of the resource from and to 
the corporate incubator. Figure 1 shows how the incubator evolved since the classic business incubators were first 
established. Kuratko and Lafollette (1987) also list four major types of incubator, these include publically sponsored, non-
profit sponsored, university-related and privately sponsored incubators. All of these examples provided tenants with 
freedom from maintenance costs, access to shared equipment and services, increased awareness of access to financial and 
technical assistance, lower anxiety of starting up alone and increase visibility of the tenant firm. Two decades later after 
Kuratko and Lafollette (1987) listed their incubator types, Ackomok (2009) provided a description of the evolution of 
incubators. Incubators have evolved from non-profit and traditional business incubators to for-profit corporate incubators 
with a specific purpose of supporting a particular industry or sector (Fig.1). Biotechnology incubators might be placed in 
close proximity to corporate incubators and venture capital incubators because of their specificity and requirement to 
make a profit.   
 
Figure 1. Evolution of Incubators 
Source (Ackomok 2009 p6) 
The evolution of incubators (Fig. 1.) shows how the purpose of an incubator changed over time. They have become less 
‘traditional’ and more ‘specific’ in terms of the tenant’s that they support and the type of support services that are 
provided. Ackomok (2009) argues that the corporate incubator is the most recent type to be established and houses a 
specific type of tenant company. Corporate incubators are units that hatch new businesses and enhance the technological 
base to assist overall development and growth to support internal start-up and entrepreneurs with promising business ideas 
or technologies. Ackomok (2009) investigated the typology and evolution of incubators and used ‘for profit’ and ‘not for 
profit’ as a framework to illustrate their evolution. Allen and McCluskey (1990) included these descriptors in their model 
and analyse these incubator types according to their primary and secondary objectives. 
2.4 Potential drivers for the creation of new biotechnology incubators  
Biotechnology incubators appeared in the UK during the early 1990’s and have appeared within emerging clusters of 
biotechnology company activity as the life science sector has grown. There are various factors that may lead to the creation 
of a new biotechnology incubator and these factors are often localised and are linked to either a source of knowledge that 
leads to the exploitation of intellectual property or the reconfiguration of the pharmaceutical industry. 
There are a number of drivers that may lead to the creation of new biotechnology incubators, these include  
i) Changes in public policy that affect the way that universities transfer and commercialise their 
intellectual property through the spin-off process 
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ii) Reconfiguration of the pharmaceutical industry, specifically changes from a closed business model of 
innovation to an open business model of innovation. 
iii) Local economic regeneration as a consequence of the closure of large research and development 
laboratories. 
2.4.1 Changes in public policy: Universities 
The mechanism that supports academic entrepreneurship is the commercialisation of technology and the application of 
information in order to undertake a specific task (Debackere & Veugelers 2005). According to Steffensen (2000) this 
normally involves a source of technology that requires specialised technical skills. A transfer of this technology to an 
organisation that does not possess these skills takes place because for whatever reason, they are unable to develop or 
create these skills themselves. The creation of a spin-out company is one example of a mechanism that supports 
technology transfer from a university to industry (Debackere & Veugelers 2005). Spin-out companies are also created to 
commercialise a specific technology which originated in either a government funded academic research and development 
laboratory, a university or a private research and development organisation. 
Government policy initiatives that have supported the growth of university based biotechnology incubators include the 
Lambert review of Business and University Collaboration (2003), Future of Higher Education white paper (2003), ‘Race 
to the Top’ Sainsbury report (2007), ‘Higher Ambitions’ initiative (2009) and the ‘Science For All’ initiative (2010). 
Other policy interventions have also contributed to the high number of biotechnology incubators that are physically 
connected to universities. These are: Universities collaborative research, centres of excellence located within universities, 
knowledge transfer partnerships (KTP), innovation voucher schemes, Knowledge Transfer Networks (KTN), 
collaborative research and development grants, industry and enterprise fellowships and CASE studentships. All of which 
were aimed to bridge the gap between industry and universities. 
In the UK, according to Lawton-Smith et al. (2005), government policy in relation to academic entrepreneurship involved 
three phases. The first phase ended the monopoly of the British Technology Group (BTG) over breakthroughs from 
publicly funded research in universities in 1983 (New Scientist 1983), along with the 1988 White Paper, DTI: Department 
for Enterprise (DTI 1988), signalled the government’s willingness for universities to display more independence in the 
commercial exploitation of intellectual property generated by their staff. Hence universities were encouraged to create 
income for themselves and contribute to national wealth creation.  
The decentralization of technology transfer represented a turning point in the development of academic entrepreneurship 
in the UK. The second phase occurred in the early in the 1990s, the White Paper Realising Our Potential (DTI, 1993) led 
to the restructuring and privatization of the national scientific laboratories and marked a shift in science policy in favour 
of universities (Lawton-Smith et al. 2005). Finally, the third piece of the jigsaw came with the election of a Labour 
administration in 1997, which marked a shift towards a regional approach to innovation with the creation of the regional 
development agencies (RDAs) and a significantly higher priority given to the knowledge economy (DTI 1998).  
2.4.1 Reconfiguration of pharmaceutical industry 
The UK has seen a shift from the traditional large pharmaceutical company model with vast research and development 
departments that carried out research ‘in-house’, with an objective to find the next blockbuster drug and hold the patent 
for 20 years. Many of these large pharmaceutical companies with operations in the UK have re-organized and closed 
some of their research and development sites for example Astra Zeneca in Loughborough, ROCHE in Hertfordshire, 
BASF in Nottingham and MERCK in Scotland.  According to Pisano (2006) pharmaceutical companies now have the 
ability to de-risk early stage drug development and are less likely to be directly involved during the very early stages of 
drug development. This had been the main driving force for the growth of the biotechnology industry in the UK. 
The past twenty years saw the emergence of the ‘biotechnology’ segment of the pharmaceutical industry, i.e. the 
industrialisation of drug research and development. Pisano (2006) proposed that the evolution of the biotechnology sector 
and the rapid increase of technology and drug in-licensing of major pharmaceutical firms has been a contributing factor 
to the growth of the sector. Recent developments in the form of changes of pharmaceutical firms’ business models to an 
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open innovation model and the closure of large pharmaceutical research and development sites have also contributed to 
the growth of the biotechnology sector. 
The pharmaceutical companies’ role has altered the dynamics of the biotechnology sector. Large pharmaceutical 
companies have started to move away from purely in-house drug research, they are now outsourcing early drug 
development, concentrating on the later stages of drug development. This new model centres around biotechnology firms 
that have the advantage of being smaller more agile companies that can change in line with market demands much quicker 
than a large pharmaceutical company. This change has provided many areas of growth for small biotechnology companies 
and the physical infrastructure for some of the UK’s largest biotechnology incubators. 
2.4.3 Local economic regeneration 
In response to the reconfiguration of the pharmaceutical industry, organisations tasked in local economic regeneration 
have become involved in the creation of new biotechnology incubators. The structural changes in the pharmaceutical 
industry had led to the closure of large research and development laboratories, accompanying these changes are job losses 
and the spill over of skills and knowledge, (Audretsch, & Keilbach 2007). Local Authorities and Regional Development 
Agencies were tasked with supporting, developing and growing their local economies. When a large pharmaceutical 
companies closes there R&D facilities there are inevitably job losses affecting highly skilled scientists and technicians. 
Organisations involved in local economic regeneration use the closure of these facilities as an opportunity to retain 
commercial and industry knowledge that would have otherwise been lost, hence new biotechnology incubators are created 
that are funded by local, regional government and European  funding.  
Regional Development Agencies were established in the early 2000’s and subsequently abolished in 2010 The RDA’s 
would provide financial support to build the physical infrastructure of biotechnology incubators and provide  soft 
infrastructure support to include networking and mentoring schemes, regional venture capital funds, incubator 
development and a Proof of Concept fund aimed at providing development funds to encourage commercialisation. In 
2003 the House of Commons Trade and Industry committee identified the importance of the biotechnology industry is 
heavily dependent on a continuous stream of high-quality basic research to provide the discoveries upon which 
commercial biotechnology is built (House of Commons 2003).   
2.6 Gaps in Literature:  
The number of biotechnology incubators in the UK has increased from five during the early 2000s to twenty five by 2017. 
There was an assumption in the literature that biotechnology incubators were primarily concerned with the 
commercialisation of predominantly university and academic life science knowledge.  The vast majority of studies 
concentrate upon individual biotechnology incubators, there are few studies that investigate all biotechnology incubators 
in the UK. Researchers have differentiated between different types of business and technology incubators however few 
have investigated biotechnology incubators. The evolution of biotechnology incubators has been taking place since the 
early 2000s however it is evident that few academic studies concentrate on UK biotechnology incubators and literature 
relating to biotechnology incubators concentrates on individual biotechnology incubators.  
There are few examples of academics investigating the phenomenon of biotechnology incubators, Feldman (2003) 
undertook a study of biotechnology incubators in Maryland USA and argued that generic incubators are not appropriate 
to life science companies, in fact they require incubators with sophisticated and costly wet laboratory space. Smith and  
Ehret (2012) investigated a biotechnology incubator in the East Midlands and showed that this particular incubator 
supported a mix of service based and intellectual property based companies.  Finally Lawton-Smith (2002) investigated 
a biotechnology incubator in Manchester, this study, like many others concentrate on either a single biotechnology 
incubator. An interesting observation of the literature is that there seems to be very few recent studies that investigate 
biotechnology incubator activity across the entire UK since the early 2000s. 
 
The rare group of studies of biotechnology incubators in the UK is centred on The East and the South East of England. 
For example Lawton-Smith (2007) concentrates on Oxfordshire, Capser et al. (2003) concentrates on the Cambridge 
Biotechnology cluster and reports released by the Office for Business Innovation and Skills (BIS) and the department of 
Trade and Industry (DTI) use case studies based on activity in the South East of England. One purpose of this study is to 
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broaden the horizon and elucidate biotechnology incubation technology in the whole regional spectrum of the UK. As far 
as can be ascertained, no research has been carried out that explores biotechnology incubator activity beyond regions 
where established clusters already exist. To address these gaps in the current literature this study will investigate the 
evolution of biotechnology incubators across the UK. 
3. Methodology: 
This study uses two desk-based surveys that provide a snap-shot of 21 biotechnology incubators taken in December 2012 
and December 2017. The surveys provide a detailed examination of the characteristics of UK biotechnology incubators 
and their tenant companies.  The surveys includes data on 480 tenant companies and their key attributes such as age, 
business model (service or IP based) and industry type (bio/pharma or med tech). Key variables for biotechnology 
incubators include the size of the incubator, number of tenant companies and the various types of technical and business 
support offered to tenants. 
Key variables for biotechnology incubators include the size of an incubator measured in square feet, number of tenants, 
technical and business support offered to tenant companies, location of incubator in terms of its geographical proximity 
to centres of expertise and knowledge such a university, hospital, a science park or a large pharmaceutical company and 
the tenant mix of the incubator. Key variables for tenant companies includes company age and business model employed 
by the tenant company (intellectual property based or service based). Additional metrics include the industry type of the 
tenant company for example biotechnology, medical technology, green technology, food technology or the provision of 
sector specific business support.  
4. Findings 
In order to describe the evolution of biotechnology incubators we must first provide a simple classification of the different 
kinds of biotechnology incubators that have appeared since the early 1990s. The classification used in this paper relates 
to the geographic proximity of the biotechnology incubator to organisations and establishments that create a particular 
kind of knowledge. Once this classification is established Biotechnology incubators operating in the UK are analyses in 
terms of their age and classification in order to illustrate trends that exist across the various types of biotechnology 
incubators.  
4.1 Classification of biotechnology incubators  
For the purposes of this paper the various UK biotechnology incubator have been classified into four groups, this 
classification relates to the proximity to particular establishments namely, universities, hospitals and pharmaceutical 
companies.  Using geographic proximity to these establishments we have devised a simple classification system to help 
illustrate the evolution of biotechnology incubators. 
Four categories of UK biotechnology incubators  
1. University based biotechnology incubators - i.e. incubators located on a university campus close to academic 
knowledge, with a role to commercial intellectual property. 
2. Hospital based biotechnology incubators - i.e. incubators located on a hospital site close to medical and clinical 
knowledge, with a role to develop medical technology products. 
3. Stand-alone biotechnology incubators - i.e. no close geographic links to a traditional sources of life science 
knowledge but close links to commercial and industry knowledge, with a role in economic and regional 
development. 
4. Large pharmaceutical company based incubators – i.e. incubators located on a currently operational 
pharmaceutical company site with close links to commercial and industry knowledge, with an open innovation 
remit. 
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4.1.1 University based biotechnology incubators 
University based incubators are usually owned by a university, based on the university or research campus and they are 
typically purpose built biotechnology incubators. University based Biotechnology incubators are likely to be small to 
medium sized (1000 to 7000 sq. m) and generally support less than 12 tenant companies. There is the potential for a 
continuous source of new spin-out companies from the university life science departments. One example is the Imperial 
Bioincubator, with its close physical connection to Imperial College University the incubator provides a steady supply of 
new tenant companies. Academic research knowledge derives from universities that are research intensive in the life 
sciences and in the UK are often Russell group universities with high research outputs in the life sciences. One example 
of how life science knowledge can be transferred from a university is the university spin-out company. This is where the 
research of an academic member of staff at the university forms the basis of a university spin-out company in order to 
‘take to market’ the outcome of academic research (McQueen et al., 1982; Steffensen et al., 2000). Quite literally 
academic knowledge is encouraged to be spun-out from the university into a new start-up company.  
4.1.2 Hospital based biotechnology incubators 
Hospital based biotechnology incubators are all physically located on a hospital site with close working relationships to 
the hospital. Clinicians or clinical nurses are often co-located within the biotechnology incubator and share facilities such 
as a café and restaurant with tenant companies. The following incubators are physically connected to a hospital site; 
CTRIC, The Cardiothoracic Bio Incubator (CTBI), Institute of Life Sciences (ILS) in Swansea (also university based) 
and Edinburgh Bioquater. The main distinguishing features of hospital based incubators are that they are usually purpose 
built and a small to medium size incubator with less than twelve tenant companies. Clinical and medical life science 
knowledge is often found close to hospitals. Clinicians that are involved in the processes of innovation and development 
of new medical products provide a source of life science knowledge that can be potentially be converted into a new life 
science company. The geographical proximity to clinical and medical knowledge potentially provides greater access to 
the NHS market for new medical devices and technologies and spill overs of tacit knowledge from practitioners located 
in the hospital.  
4.1.3 Stand-alone biotechnology incubators 
Stand-alone biotechnology incubators are not usually purpose built. Typically they are based in former large 
pharmaceutical company research and development laboratories that have been converted into biotechnology incubators. 
Since the late 1990s big names in the pharmaceutical industry such as MERCK, BASF, ROCHE and Astra Zeneca 
consolidated large sections of their UK research and development activities. The following examples detail some of the 
closures in the UK. Although many of these big pharmaceutical companies have recently closed their research and 
development facilities, the buildings and their very expensive laboratory facilities have not been indefinitely closed or 
destroyed, they have found a new use.  For each of the large pharmaceutical companies previously mentioned, a 
regeneration of the facilities has taken place. They provide a space that facilitates biotechnology company start-ups and 
provides the necessary physical infrastructure to support a growing biotechnology sector. Stand-alone incubators have 
the highest proportion of business support tenants, between 26% and 32% of tenants that offer some type of business 
support and are amongst the largest in size providing up to 60,000sq m of case and housing up to 70 tenant companies.  
4.1.4 Large pharmaceutical biotechnology Incubators 
Large pharmaceutical biotechnology incubators are co-located on fully operational sites owned and operated by large 
pharmaceutical companies such as GlaxoSmithKline (GSK) in Stevenage and AstraZeneca (AZ) in Manchester. The aim 
of these types biotechnology incubators is to create networks that can facilitates the transfer and absorption of commercial 
and industry life science knowledge by using an ‘open’ model of innovation. New and emerging life science companies 
have the opportunity to interact with well-established large pharmaceutical companies in addition to the more traditional 
support provided within a biotechnology incubators. New life science companies have access to additional routes to 
market via the large pharmaceutical company as well as the potential access to technical knowhow and technical 
equipment that large pharma possess. In turn, this arrangement provides large pharmaceutical companies with access to 
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early stage drug development pipeline without the risks and high attrition rates associated with early stage research and 
development. 
4.2 Evolution of biotechnology incubators 
The evolution of biotechnology incubators in the UK is illustrated in table 1, this shows the appearance of subsequent 
generations of biotechnology incubators from 1998 to 2016. This table shows the year each biotechnology incubator was 
opened and the institution the incubator is physically connected to.  During the late 1990s and early 2000s there were 
only a few biotechnology incubators that were specifically designed to support new life science firms. Sainsbury (1999) 
and Cooke (2001) noted that there were only a handful in operation throughout the UK hence their presence did not appear 
to play a significant role in the growth of the life science industry or biotechnology sector in the UK during this period. 
By 2010 there were at least thirteen biotechnology incubators operating in the UK and by 2016 there were twenty-one. 
Table 1. Generations of biotechnology incubators 
Biotechnology Incubator  Institution Date Opened 
First Generation - University based biotechnology incubators 
Imperial Incubator (London) Imperial College London 2006 
London Bioscience Innovation Centre Royal Veterinary College 2001 
Mersey Bio Incubator University of Liverpool 2004 
Queen Mary Bio science Innovation Centre Queen Mary University of London 2008 
Sheffield Bio Incubator University of Sheffield 2006 
Bradford Laboratories University of Bradford 2006 
Babraham Bioscience incubator Babraham institute 1998 
Second Generation - Hospital based biotechnology incubator 
Cardiff Medicentre Heath Hospital 1992 
Cardiothoracic bio Incubator (Papworth) Papworth Hospital 2006 
C-TRIC (Northern Ireland) Altnagwlvin Hospital 2009 
ILS (Swansea) Singleton Hospital 2012 
Edinburgh bio Quarter Edinburgh Royal Infirmary 2013 
Third Generation – Stand alone biotechnology incubator 
BioCity Nottingham Former BASF/Boots 2003 
BioPark Hertfordshire  Former ROCHE 2006 
DiagNox (Oxford) Purpose Built 2003 
CELS Bio Incubator (Newcastle) Purpose Build 
 
BioCity Scotland Former MERCK 2011 
Fourth Generation Large pharmaceutical biotechnology incubators 
Stevenage Bioscience Catalyst GlaxoSmithKline 2011 
BioHub (Alderley Park) AstraZeneca 2014 
Medicity (Boots) Boots 2013 
 
The data from table 1 has been used to analyse the age of biotechnology incubators within each generation.  Figure 2 
shows the average age for each incubator type and the biotechnology incubators that have been in operation for the least 
amount of time (newest) and the most amount of time (oldest). Figure 2 shows that the average age of university based 
incubators in 15 years with the oldest incubator opening 26 years ago. The average age of the stand-alone incubators is 
13 years with the oldest incubator opening 15 years ago. The most recent type of biotechnology incubators to appear are 
the large pharmaceutical based incubators with an average age of 4 years and the oldest incubator in this generation was 
only opened 7 years ago. 
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Figure 2. Age of biotechnology incubator 
4.3 Successive generations of biotechnology incubators 
First generation biotechnology incubators are university based incubators that are closely related to academic 
entrepreneurship and the commercialisation of university created intellectual property. The rollout of government policy 
initiatives between 2003 and 2010 coincide with the appearance of university based biotechnology incubators. Initiatives 
such as the Lambert review of Business and University Collaboration (2003), Future of Higher Education white paper 
(2003), ‘Higher Ambitions’ initiative (2009) and the ‘Science For All’ initiative (2010) supported the creation of these 
biotechnology incubators. University based incubators were mainly established between 1998 and 2006 with changes in 
public policy that encouraged the commercialisation of intellectual property through spin-off companies as a major driver. 
Second generation biotechnology incubators are hospital based incubators, these are closely related to clinical and medical 
knowledge. It seems that there has not been the same clear time frame for specific policy initiates that led to the creation 
of hospital based biotechnology incubators. These incubators have appeared over a much wider time span, hospital based 
incubators first appeared in 1992 and the most recent opened in 2013. These incubators are often associated with the 
development of medical products and devices and provide close links to clinical nurses and clinicians. 
Third generation biotechnology incubators are stand-alone incubators, these are mainly facilities that re-use former 
pharmaceutical research and development laboratories, there are two examples of stand-alone incubators that are purpose 
built however these are often significantly smaller than former large pharmaceutical R&D laboratories. The driver for 
these incubators is local economic regeneration with regional government between 2003 and 2002 heavily involved during 
the inception phase and providing substantial financial assistance to repurpose the former laboratories. 
Fourth generation biotechnology incubators are large pharmaceutical incubators, these are closely related to industry and 
commercial knowledge. They are the most recent type of biotechnology incubator and first appeared in 2012, they are 
located on the sites of existing pharmaceutical companies that are currently in operation such as GSK and AstraZeneca. 
The main driver for these fourth generation biotechnology incubators is the shift in large pharmaceutical companies from 
a vertically integrated, closed business model of drug research and development to an open model. This open model of 
innovation provides more opportunities for smaller life science firms seeking an acquisition or licensing deals in order to 
capture the value of their intellectual property. 
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5. Conclusion 
This paper investigates the changing landscape of biotechnology incubators in the UK and evidences their evolution from 
1999 to 2017. Biotechnology incubators were initially created for the primary purpose of commercialising intellectual 
property within a university and to develop new medical technology products created by academics researchers and 
clinicians. The role of biotechnology incubators has evolved to include economic regeneration objectives and the 
facilitation open innovation within the pharmaceutical industry.  This study evidences the changing policy environment 
for biotechnology incubators and begins to investigate the evolution of UK biotechnology incubators from facilities that 
primarily support the commercialisation of intellectual property to facilities that reuse former pharmaceutical research 
and development laboratories and collocate with operational pharmaceutical companies. 
This study evidences the growth of biotechnology incubators from five in 2000 to twenty-one in 2017.  We propose that 
regional and national policy initiatives and changes in the business model of large pharmaceutical companies have been 
the main drivers for the evolution of biotechnology incubators in the UK. Initially biotechnology incubators were co-
located on university and hospital sites for the primary purpose of commercialising intellectual property and product 
development. Then there were several new biotechnology incubators with an economic regeneration remit, usually 
making use of redundant pharmaceutical R&D laboratories. More recently we have observed the appearance of corporate 
biotechnology incubators co-located on operational pharmaceutical research and development sites with an open 
innovation remit e.g. Astra Zeneca (Manchester), GlaxoSmithKline (Stevenage) and Boots (Nottingham).  
This study extends the work undertaken by Akcomak (2009) in terms of the evolution of incubators and provides the 
groundwork for further investigation into characteristics and roles of this new type’s biotechnology incubator. This 
evidence can be used to differentiate between the types of biotechnology incubators in the UK and is potentially useful 
for policy makers and organisations involved in supporting new life science companies because it provides a greater 
degree of granularity and precision when classifying biotechnology incubation processes. This study can provide policy 
makers with evidence for better informed decisions in terms of supporting new and emerging life science industry in their 
regions. 
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